TITLE:
Proteinuria in Children Living with HIV on Highly Active Antiretroviral Therapy (Haart)
AUTHORS:
Lucie Charlotte Ollandzobo Ikobo, Roland Bienvenu Ossibi Ibara, Neli Yvette Ngakengni, Laren Babomi, Gaston Ekouya Bowassa, Linda Tchidjo Ngamo, Steve Vassili Missambou Mandilou, Sabrina Nadia Bouithy, Evrard Romaric Nika, Jean Robert Mabiala Babela
KEYWORDS:
Children, HIV, HAART, Associated Factors, Proteinuria
JOURNAL NAME:
Open Journal of Pediatrics,
Vol.10 No.2,
May
8,
2020
ABSTRACT: Objective: To determine the prevalence of proteinuria in children living with HIV
(CLHIV) and identify associated factors. Patients and methods: This was
a cross-sectional, descriptive and analytical study carried out from April to
August 2017 in the HIV care centres in Brazzaville and Pointe-Noire. The study
included CLHIV with dipstick urinalysis test “Combur10 Test® M”. Results: Thirty seven CLHIV on HAART presented a
proteinuria, 21.8%. Children were male gender in 21 cases (56.8%) and female gender in 16 cases (43.2%). Mean age was 10.9 ± 3.9
years. The children were infected with type 1 virus in 35 cases (94.6%),
vertical transmission in all the cases (100%). Children were living with HIV
for about 2 to 4 years of average n = 18 (48.6%) and
they were WHO clinical stage 2 in 18 cases (48.6%). 13 children (35%) had CD4
level 3. All CLHIV (100%) were on HAART thus 20
(37.7%) on the combination of zidovudine (AZT), lamivudine (3TC) and nevirapine
(NVP). This combination AZT, 3TC, NVP was a protective factor regarding the
occurrence of proteinuria (OR: 0.43; IC (95%). Conclusion: Proteinuria is less observed in
CLHIV on HAART. Systematic screening and early management of proteinuria during
follow-up of these children improve their survival.